Ann: Outstanding Results Achieved in Second JHC Clinical Trial, page-70

Thanks mate, appreciate the response. If I’m honest HMD is overweight in my portfolio, as I bought on FDA approval then averaged down a fair bit through the COVID dip and haven’t sold any. That probably won’t stop me from averaging down more if people want to part with their stock at silly prices. I’m very aware this could all end up as nothing, I’ve held shares in companies like Oventus that have a great product and looked like they might figure out the market but never did. I do have conviction here though, otherwise I wouldn’t be holding. The product, the market, the business model and most importantly the foot in the door with a number of genuinely massive potential buyers just line up too well.